New consensus document for appropriate use of drug testing in clinical addiction medicine

June 1, 2017, Wolters Kluwer Health

A new Consensus Document from the American Society of Addiction Medicine (ASAM) provides practical, evidence-based recommendations on the use of drug testing for identification, diagnosis, treatment, and monitoring of patients with or at risk for substance use disorders (SUDs). The document appears in the May/June issue of the Journal of Addiction Medicine, the official journal of ASAM.

"Drug testing is a valuable tool for supporting patients in treatment, and this comprehensive set of recommendations should prove useful to providers in a variety of addiction treatment settings," comments Margaret Jarvis, MD, DFASAM, Chair of ASAM's Quality Improvement Council. The Consensus Document and supplemental digital content are available on Journal of Addiction Medicine and ASAM websites.

Evidence-Based Recommendations Aim at 'Smarter' Approach to Drug Testing

The Consensus Document provides practical guidance on the use of across the many clinical settings in which addiction treatment is provided. Based on evidence from more than 100 research studies, the document's recommendations were developed by a multidisciplinary panel, following an established "Appropriateness Method" process that combines scientific evidence with the collective judgment of experts.

The resulting recommendations focus on "when, where and how often it is appropriate to perform testing" in clinical . Based on evidence that drug testing aids in monitoring adherence and abstinence in treatment and can improve patient outcomes, drug testing "should be widely used in addiction treatment settings." Drug testing should serve as a therapeutic tool, rather than a punitive one: "Providers should utilize drug testing to explore denial, motivation, and actual substance use behaviors with patients."

Drug testing plays important roles in initial assessment, treatment planning, and monitoring of patients with SUDs, across treatment settings. However, the document emphasizes, "Drug testing should be only one of several methods of detecting substance use or monitoring treatment," including patient self-reports and other indicators.

The Consensus Document addresses a wide range of daily issues encountered in the process of drug testing, including the choice of tests and appropriate response to test results. Urine tests remain by far the most common category of tests, but are also the most prone to tampering. There is growing interest in using other types of samples for drug testing, although more evidence on these tests is needed.

Drug testing should be done at least weekly at the beginning of treatment, and at least monthly in patients in stable recovery; however, individual consideration may be given for less frequent testing if a patient is in stable recovery. The document recommends that testing be performed on a random schedule, when possible.

The document addresses many other elements of testing programs, including documentation and patient confidentiality, practitioner education and expertise, and facilities and devices. Issues in inpatient and outpatient treatment as well as opioid treatment services are discussed, along with issues related to special populations, including adolescents, pregnant , people in recovery, and health and other professionals. The expert panel also makes recommendations for further research to address gaps in each area.

A previous ASAM White Paper made broad suggestions to improve drug testing in clinical practice, emphasizing a "smarter" approach to drug testing—including avoiding some inappropriate and high-cost practices followed in the past. "The current crisis has many people in desperate need of high-quality addiction care, but many, professionals included, have no way of judging the quality of this kind of ," comments Dr. Jarvis. "This helps to define that high-quality care."

Explore further: Medications to treat opioid use disorders—new guideline from the American Society of Addiction Medicine

More information: undefined undefined. Appropriate Use of Drug Testing in Clinical Addiction Medicine, Journal of Addiction Medicine (2017). DOI: 10.1097/ADM.0000000000000322

Related Stories

Medications to treat opioid use disorders—new guideline from the American Society of Addiction Medicine

September 24, 2015
Medications play an important role in managing patients with opioid use disorders, but there are not enough physicians with the knowledge and ability to use these often-complex treatments. New evidence-based recommendations ...

Opioid use disorder in pregnancy—Medication treatment improves outcomes for mothers and infants

April 14, 2017
Medication for addiction treatment (MAT) with buprenorphine or methadone is an appropriate and accepted treatment for pregnant women with opioid use disorder (OUD), according to a research review and update in the Journal ...

Longer addiction treatment is better, study confirms

March 4, 2017
(HealthDay)—The longer patients receive treatment for addiction, the greater their chances of success, a new study finds.

Study explores drug users' opinions on genetic testing

September 23, 2014
Genomic medicine is rapidly developing, bringing with its advances promises of individualized genetic information to tailor and optimize prevention and treatment interventions. Genetic tests are already guiding treatments ...

Good outcomes with 'telepsychiatry' in medical treatment of opioid use disorder

January 25, 2017
For people with opioid use disorder receiving medication treatment with buprenorphine, a telepsychiatry approach—using videoconferencing as an alternative to in-person group sessions—provides similar clinical outcomes, ...

Use of psychosocial treatments in conjunction with medication for opioid addiction—recommended, but research is sparse

January 26, 2016
Psychosocial interventions, used together with effective medications, are a key part of recommended treatment for opioid addiction. But while research generally supports the effectiveness of psychosocial treatments, there ...

Recommended for you

Buprenorphine may be safer than methadone if treatment duration is longer, study suggests

April 20, 2018
The less commonly prescribed opioid substitute buprenorphine may be safer than methadone for problem opioid users, especially if used during the first month of treatment, according to a study which includes University of ...

Binge-eating mice reveal obesity clues

April 9, 2018
Obesity is a growing issue in many countries, accelerated by easy access to calorie-dense foods that are pleasurable to eat (known as an 'obesogenic environment'). But while it's clear that eating too much leads to weight ...

New research finds drug for alcohol use disorder ineffective

February 26, 2018
A new study, published in the Addiction journal, conducted by researchers from the University of Liverpool highlights the ineffectiveness of a specific drug treatment for alcohol use disorders.

Most PA students tobacco-free, but vaping and cigarette use still a concern

February 26, 2018
Most of Pennsylvania's high school and middle school students are tobacco-free, but the use of cigarettes, and their digital counterpart, e-cigarettes, is still a cause for concern, according to Penn State researchers.

Cannabinoids are easier on the brain than booze, study finds

February 9, 2018
Marijuana may not be as damaging to the brain as previously thought, according to new research from the University of Colorado Boulder and the CU Change Lab.

Marijuana use may not aid patients in opioid addiction treatment

December 4, 2017
Many patients who are being treated for opioid addiction in a medication-assisted treatment clinic use marijuana to help manage their pain and mood symptoms.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.